Sterling Investment Management LLC Makes New $882,000 Investment in Pfizer Inc. $PFE

Sterling Investment Management LLC acquired a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 35,431 shares of the biopharmaceutical company’s stock, valued at approximately $882,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Horizon Financial Services LLC raised its position in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $28,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer in the 3rd quarter valued at approximately $29,000. Darwin Wealth Management LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at approximately $32,000. Finally, True Wealth Design LLC raised its position in shares of Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.1%

Shares of Pfizer stock opened at $26.31 on Tuesday. The firm has a market capitalization of $149.61 billion, a PE ratio of 19.35 and a beta of 0.35. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm’s 50 day moving average is $27.17 and its 200 day moving average is $26.11. Pfizer Inc. has a 1 year low of $21.97 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s payout ratio is 126.47%.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. CICC Research assumed coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research report on Monday, March 2nd. Barclays assumed coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price for the company. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Finally, Guggenheim lifted their price target on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.74.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported strong first-quarter results and reaffirmed its full‑year 2026 guidance, with CEO Albert Bourla highlighting R&D progress and pipeline momentum — a direct support for near‑term revenue visibility and investor confidence. Read More.
• Positive Sentiment: Q1 profit topped Wall Street estimates, helped by sustained demand for legacy drug Eliquis — showing Pfizer can still drive cash flow from established franchises even as it builds newer growth drivers. Read More.
• Positive Sentiment: Pfizer and Arvinas won FDA approval for VEPPANU (vepdegestrant), a first‑of‑its‑kind therapy for ESR1‑mutated advanced breast cancer — a meaningful commercial and strategic win for Pfizer’s oncology portfolio. Read More.
• Neutral Sentiment: Analysts remain generally bullish on Pfizer’s pipeline (including obesity opportunities); investors will watch management commentary on pipeline timelines and guidance as catalysts. Read More.
• Neutral Sentiment: Pre‑market coverage flagged Pfizer among stocks to watch and dividend‑oriented trade ideas; the company’s high yield attracts income investors even as growth questions persist. Read More.
• Negative Sentiment: Commentary from TV and opinion sources questions whether Pfizer’s dividend is compelling versus fixed‑income alternatives (e.g., “If I want good yield, I’ll buy a bond”), a narrative that can pressure income‑sensitive holders and mute upside. Read More.
• Negative Sentiment: Longer‑term critiques (e.g., “priced like dead money”) highlight investor concerns about secular growth prospects and valuation, which can cap multiple expansion despite strong cash generation. Read More.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.